文献速递白血病造血干细胞移植与细胞治疗

首次完全缓解期高危急性髓系白血病异基因造血干细胞移植的替代供者选择

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1.
PubMed 文献 · Blood Adv · 2017-02-28

该研究比较6545例首次完全缓解期高危急性髓系白血病成人患者接受不同供者类型异基因造血干细胞移植的结局。2年总生存率在同胞全合供者、10/10相合无关供者及单倍体供者间无显著差异,而9/10相合无关供者和脐带血移植的2年总生存率显著较低。非复发死亡率在替代供者中显著高于同胞全合供者。作者认为同胞全合和10/10相合无关供者仍可能优先选择,若无则替代供者包括9/10相合无关供者、脐带血和单倍体供者。

要点

  • 同胞全合供者、10/10相合无关供者和单倍体供者移植后2年总生存率无显著差异。
  • 9/10相合无关供者和脐带血移植的2年总生存率显著低于同胞全合供者。
  • 替代供者的非复发死亡率显著高于同胞全合供者,单倍体供者结局已接近相合供者。

核心结论

  • 同胞全合供者和10/10相合无关供者移植在高危急性髓系白血病首次完全缓解期患者中仍可能优先选择。
  • 若无同胞全合或10/10相合无关供者,替代供者包括9/10相合无关供者、脐带血移植和单倍体供者。
  • 单倍体供者应用日益增多,其结果目前已接近相合供者。

研究设计与样本

  • 研究比较6545例接受异基因造血干细胞移植的高危急性髓系白血病首次完全缓解期成人患者,按供者类型分组:同胞全合供者3511例、10/10相合无关供者1959例、9/10相合无关供者549例、脐带血移植333例、单倍体供者193例。

主要发现

  • 同胞全合供者移植后2年总生存率为59±1%,与10/10相合无关供者的57±1%和单倍体供者的57±4%无显著差异。
  • 9/10相合无关供者移植后2年总生存率为49±2%,脐带血移植为44±3%,均显著低于同胞全合供者(P<.001)。
  • 2年非复发死亡率在单倍体供者移植后为26±3%,脐带血移植后为29±3%,而同胞全合供者移植后为15±1%。
  • 多因素分析证实供者类型的影响,同胞全合供者、10/10相合无关供者和单倍体供者移植后总生存率无统计学显著差异。
  • 替代供者的非复发死亡率显著高于同胞全合供者移植。

临床怎么用

  • 作者认为,对于首次完全缓解期高危急性髓系白血病患者,同胞全合供者和10/10相合无关供者移植仍可能优先选择。
  • 作者指出,若无同胞全合或10/10相合无关供者,替代供者包括9/10相合无关供者、脐带血移植和单倍体供者。
  • 作者提到,单倍体供者应用日益增多,其结果目前已接近相合供者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the treatment of choice to consolidate remission in patients with poor-risk acute myeloid leukemia (AML). With increasing alternative donors available, the preferred donor or stem cell source is debated. We set out to study outcome in recipients of alloHSCT with poor-risk AML in first complete remission (CR1) by donor type. A total of 6545 adult patients with poor-risk AML in CR1 receiving an alloHSCT using matched related donor (MRD, n = 3511) or alternative donors, including 10/10 (n = 1959) or 9/10 matched unrelated donors (MUDs, n = 549), umbilical cord blood (UCB) grafts (n = 333), or haplo-identical (haplo) donors (n = 193) were compared. Overall survival (OS) at 2 years following MRD alloHSCT was an estimated 59 ± 1%, which did not differ from 10/10 MUD (57 ± 1%) and haplo alloHSCT (57 ± 4%). OS, however, was significantly lower for 9/10 MUD alloHSCT (49 ± 2%) and UCB grafts (44 ± 3%), respectively (P < .001). Nonrelapse mortality (NRM) depended on donor type and was estimated at 26 ± 3% and 29 ± 3% after haplo alloHSCT and UCB grafts at 2 years vs 15 ± 1% following MRD alloHSCT. Multivariable analysis confirmed the impact of donor type with OS following MRD, 10/10 MUD, and haplo alloHSCT not being statistically significantly different. NRM was significantly higher for alternative donors as compared with MRD alloHSCT. Collectively, these results suggest that alloHSCT with MRDs and 10/10 MUDs may still be preferred in patients with poor-risk AML in CR1. If an MRD or 10/10 MUD is not available, then the repertoire of alternative donors includes 9/10 MUD, UCB grafts, and haplo-identical donors. The latter type of donor is increasingly applied and now approximates results with matched donors.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Versluis J, Labopin M, Ruggeri A, et al. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv. 2017. PMID: 29296964. doi:10.1182/bloodadvances.2016002386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。